Travere Therapeutics TVTX
NASDAQ TVTX
$58.86 -1.13 (-1.88%)
At close: Sep 30, 2026 · 4:00 PM EDT

Travere Therapeutics (TVTX) EV to EBITDA (2026)

Updated

Travere Therapeutics' (TVTX) EV to EBITDA came in at 228.36 for Q2 2026, up 37.8% from the prior quarter.

Analysis

Travere Therapeutics (TVTX) EV to EBITDA (2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EV to EBITDA at Travere Therapeutics was 216.03.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Travere Therapeutics 5.65 Bn 5.25 Bn 167.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 228.36
Mar 31, 2026 165.74
API Access

Travere Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=TVTX&period=max&api_key=YOUR_API_KEY